AdvisorShares Psychedelics ETF (ARCA: PSIL)

Ultime notizie per AdvisorShares Psychedelics ETF (ARCA:PSIL)

AdvisorShares Psychedelics ETF

Healthcare

Other

The Fund is an actively managed exchange-traded fund (ETF) that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in (i) securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and (ii) derivatives that have economic characteristics similar to such securities. The Fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The Fund invests in exchange-listed equity securities, including common and preferred stock of U.S. and foreign mid, small and micro-capitalization companies, and in total return swaps intended to provide exposure to such companies.

Mind Medicine Mindmed Inc

Compass Pathways Plc Adr

Gh Research Plc

NRX Pharmaceuticals Inc.

Intra-Cellular Therapies Inc

Atai Life Sciences BV

Alkermes Plc

Vistagen Therapeutics Inc.

ADVISORSHARES PSYCHEDELICS ETF

Psychedelics

Broad U.S. Equity ETFs

Markets

ETFs

AMZN

GOOGL

NERD

PLTR

PLTU

PSIL

RBLX

SIXG

TTWO

In un contesto di incertezza economica, alcuni fondi di investimento hanno dimostrato una notevole resilienza.

Turbolenze di mercato? No problem: 5 ETF che hanno guadagnato bene la scorsa settimana

<p>JP Morgan  analyst Samik Chatterjee   maintains LKQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) with a Overweight and lowers the price target from $50 to $48.</p>


News

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on LKQ, Lowers Price Target to $48

SOS Enters Into Strategic Partnership Framework Agreement With Lepu Sodium Power To Optimize Electricity Use

THRY

Thryv And 1-800Accountant Enter Into Partnership Designed To Optimize Small Business Growth

Guidance

Events

SHOP

Shopify CFO Says Expect The Move To 3-month Trials And Lack Of Substantive Pricing Changes In 2025 To Impact Subscription Solutions Growth

<p>JP Morgan  analyst Ella Smith   maintains LegalZoom.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZ#NASDAQ">LZ</a>) with a Overweight and raises the price target from $9 to $11.</p>


JP Morgan Maintains Overweight on LegalZoom.com, Raises Price Target to $11

WIIM

Treasure Global Inc. shares are trading higher after the company announced the acquisition of a 51% controlling stake in Tien Ming Distribution Sdn Bhd.

<p><i>Strategic Expansion into Malaysia's USD159 Billion FMCG Industry &amp; High-growth E-commerce Market.</i></p>
<p><i>Projected USD116 Million Revenue Over Three Years Through Integration with F&amp;N's USD1.16 Billion Annual Sales.</i></p>
<p><i>Strengthening Treasure Global's Logistics and Digital Commerce Capabilities Through Tien Ming Distribution.</i></p>


Treasure Global Expands Into FMCG & E-Commerce With 51% Stake In Tien Ming Distribution

<p>Oppenheimer  analyst Noah Kaye   maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Outperform and raises the price target from $300 to $320.</p>


Oppenheimer Maintains Outperform on Rockwell Automation, Raises Price Target to $320

Biotech

General

ARTL

Artelo Biosciences Will Be Presenting Data On ART12.11, A Proprietary Cocrystal Composed Of Cannabidiol And Tetramethylpyrazine , At The International Medical Cannabis Conference , February 13-14, 2025

<p>RBC Capital  analyst Brian Abrahams   maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Sector Perform and lowers the price target from $70 to $68.</p>


INCY

RBC Capital Maintains Sector Perform on Incyte, Lowers Price Target to $68

AAPL

BABA

Apple and Alibaba shares are trading higher following a report from The Information indicating the companies partnered to develop AI features for iPhone user in China.

RGTI

Rigetti and Qblox Publish Joint Research Demonstrating Ability To Redout Superconducting Qubits With Optical Transducer In Nature Physics

<p>JP Morgan  analyst John Ivankoe   maintains McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Overweight and raises the price target from $280 to $300.</p>


JP Morgan Maintains Overweight on McDonald's, Raises Price Target to $300

'Apple Partners With Alibaba to Develop AI Features for iPhone Users in China' -The Information

<p>Oppenheimer  analyst Param Singh   initiates coverage on IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with a Outperform rating and announces Price Target of $320.</p>


Initiation

Oppenheimer Initiates Coverage On IBM with Outperform Rating, Announces Price Target of $320

<p>In the last three months, 8 analysts have published ratings on Health Catalyst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $9.38, with a high estimate of $12.00 and a low estimate of $7.00. This current average has decreased by 10.67% from the previous average price target of $10.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739282614_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Health Catalyst by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.50</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$9.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Health Catalyst. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Health Catalyst compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Health Catalyst's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Health Catalyst's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HCAT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Health Catalyst analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Health Catalyst</h2>
<p>Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.</p>
<h3>Health Catalyst's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Health Catalyst's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>3.5%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Health Catalyst's net margin is impressive, surpassing industry averages. With a net margin of <strong>-19.29%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Health Catalyst's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-4.14%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-1.96%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Health Catalyst's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.03</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


HCAT

Beyond The Numbers: 8 Analysts Discuss Health Catalyst Stock

<p>Throughout the last three months, 10 analysts have evaluated Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $73.3, a high estimate of $85.00, and a low estimate of $65.00. This upward trend is evident, with the current average reflecting a 13.82% increase from the previous average price target of $64.40.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739282603_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A comprehensive examination of how financial experts perceive Lattice Semiconductor is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>David Williams</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$70.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>John Vinh</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Ruben Roy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Tristan Gerra</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$56.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lattice Semiconductor. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Lattice Semiconductor compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Lattice Semiconductor's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Lattice Semiconductor's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LSCC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Lattice Semiconductor analyst ratings.</strong></a></p>
<h2>About Lattice Semiconductor</h2>
<p>Lattice Semiconductor Corp is a developer of semiconductor technology that it distributes through products, solutions, and licenses. The company reaches its customers through consumer, communications, and industrial markets. The company has one operating segment namely the core Lattice business that includes silicon-based and silicon-enabling products, evaluation boards, development hardware, and related intellectual property licensing, services, and sales. The products of the company are offered globally; and, the majority of sales are derived from customers in Asia.</p>
<h3>Breaking Down Lattice Semiconductor's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Lattice Semiconductor faced challenges, resulting in a decline of approximately <strong>-33.87%</strong> in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Lattice Semiconductor's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>5.66%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Lattice Semiconductor's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>1.03%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Lattice Semiconductor's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.86%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Lattice Semiconductor's debt-to-equity ratio is below the industry average. With a ratio of <b>0.03</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


LSCC

Forecasting The Future: 10 Analyst Projections For Lattice Semiconductor

<p>RBC Capital  analyst Nik Modi   maintains Edgewell Personal Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>) with a Outperform and lowers the price target from $48 to $43.</p>


RBC Capital Maintains Outperform on Edgewell Personal Care, Lowers Price Target to $43

<p>In the last three months, 4 analysts have published ratings on Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $14.12, a high estimate of $16.00, and a low estimate of $12.50. This current average represents a 13.11% decrease from the previous average price target of $16.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739282588_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Harmonic. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Savageaux</td>
<td>Northland Capital Markets</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$12.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Steve Frankel</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Harmonic. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Harmonic compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Capture valuable insights into Harmonic's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HLIT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Harmonic analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Harmonic: A Closer Look</h2>
<p>Harmonic Inc designs and manufactures video infrastructure products and system solutions to deliver video and broadband services to consumer devices. The firm operates in two segments: Video, which sells video processing, production, and playout solutions to cable operators and satellite and telecommunications providers; and Broadband which sells broadband access solutions and related services. Majority of the revenue generated from the company is from United States.</p>
<h3>A Deep Dive into Harmonic's Financials</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Harmonic showcased positive performance, achieving a revenue growth rate of <strong>53.89%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Harmonic's net margin excels beyond industry benchmarks, reaching <strong>11.09%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Harmonic's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>5.29%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.95%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Harmonic's debt-to-equity ratio is below the industry average at <strong>0.35</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


HLIT

4 Analysts Have This To Say About Harmonic

Shopify CFO Says Saw Higher Cloud And Infrastructure Hosting Costs In Part To Support Higher Volumes In Q4; Do Not Expect Higher Cloud And Infrastructure Hosting Costs To Have As Much Of An Impact Going Forward

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><em>The New York Times </em>published an article in early February about mental health and the failure of New York City to carefully <a href="https://www.nytimes.com/2024/02/08/nyregion/newyorktoday/mentally-ill-homeless.html">audit its program</a> to treat mentally ill people living on the streets. When I read articles like this, it makes me think about possible related investments. Specifically, in this case, mental health stocks.&nbsp;</p>



<p>It could be a drug company that&rsquo;s got a treatment for mental health that&rsquo;s working for patients. Another possibility is operators of mental health facilities. However, it would be false to say that I&rsquo;ve spent much time researching stocks in this niche area, so I&rsquo;m relatively unaware of the possibilities.</p>



<p>AdvisorShares <a href="https://advisorshares.com/etfs/psil/">launched</a> the <strong>AdvisorShares Psychedelics ETF </strong>(NYSEARCA:<span><a href="https://investorplace.com/stock-quotes/psil-stock-quote/"><strong>PSIL</strong></a></span>) in September 2021. The shares could have done better, losing 85% of their value, trading around $1.50. PSIL invests in the emerging psychedelic drugs sector.&nbsp;</p>



<p>As someone who supports the Law Enforcement Action Partnership, which focuses on moving <a href="https://lawenforcementactionpartnership.org/about-us/mission-and-vision/">beyond the war on drugs</a>, I believe ETFs like PSIL are vital to supporting companies that are working to reduce the damage caused by addiction and poor mental health.&nbsp;&nbsp;</p>



<p>Unfortunately, PSIL hasn&rsquo;t met a better fate, but investing is about profits, not losses.&nbsp;</p>



<p>On the plus side, the holdings from PSIL gave me one of my three mental health stocks to buy to help change the world.&nbsp;&nbsp;</p>



<h2>Bristol Myers Squibb (BMY)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/09/bmy1600b-300x169.jpg" alt="Bristol-Myers (BMY) logo at the top of a cellphone."><div>Source: Piotr Swat / Shutterstock.com</div></div>


<p><strong>Bristol Myers Squibb </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/bmy-stock-quote/"><strong>BMY</strong></a></span>) is the biggest of the three stocks.</p>



<p>In December, it <a href="https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Strengthens-Neuroscience-Portfolio-with-Acquisition-of-Karuna-Therapeutics/default.aspx">announced</a> the acquisition of <strong>Karuna Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/krtx-stock-quote/"><strong>KRTX</strong></a></span>) for $14.0 billion, or $12.7 billion after cash. The $330 price per share is a 53% premium to Karuna&rsquo;s share price on Dec. 21, 2023.&nbsp;</p>



<p>Karuna is focused exclusively on developing medicines for people living with psychiatric and neurological conditions. The company&rsquo;s KarXT New Drug Application (NDA) for treating schizophrenia in adults was accepted by the Food and Drug Administration (FDA) for review by September 2024.&nbsp;&nbsp;</p>



<p>As Bristol Myers press release states, KarXT is in registrational trials both for adjunctive therapy to the existing standard of care agents in schizophrenia and for the treatment of psychosis in patients with Alzheimer&rsquo;s disease.</p>



<p>Bristol Myers is accelerating its participation in neuroscience. The acquisition of Karuna and KarXT should contribute significantly to the company&rsquo;s revenue growth in the second half of the 2020s and into the 2030s. Bristol Myers CEO Christopher Boerner stated:</p>




<p>&ldquo;This transaction fits squarely within our business development priorities of pursuing assets that are strategically aligned, scientifically sound, financially attractive, and have the potential to address areas of significant unmet medical need.&rdquo; </p>




<h2>Acadia Healthcare (ACHC)</h2>


<div><img width="300" height="165" src="https://investorplace.com/wp-content/uploads/2017/10/achcmsn-300x165.jpg" alt=""><div>Source: Shutterstock</div></div>


<p><strong>Acadia Healthcare </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/achc-stock-quote/"><strong>ACHC</strong></a></span>) was founded in <a href="https://www.acadiahealthcare.com/about/">Jan. 2005</a> in Franklin, TN. It provides psychiatric and chemical dependency services to its patients through inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, outpatient clinics and therapeutic school-based programs.</p>



<p>The company operates <a href="https://www.acadiahealthcare.com/investors/">253 behavioral healthcare facilities</a> with approximately 11,100 beds in 39 states and Puerto Rico. It is the <a href="https://acadiahealthcare.gcs-web.com/static-files/61e71a13-989a-4493-a296-f8e936673b63">largest</a> behavioral health-focused provider in the country, treating roughly 75,000 people per day.&nbsp;</p>



<p>Approximately 51% of its $2.9 billion in trailing 12-month income through Sept. 30, 2023, is for acute care, followed by specialty (21%), comprehensive treatment centers (17%), and residential treatment centers (11%).</p>



<p>Its plan is three-fold: 1) grow the number of facilities through joint ventures and new builds, 2) expand its level of care for substance abuse disorders, and 3) leverage technology to improve patient care.&nbsp;</p>



<p>As U.S. Surgeon General Dr. Vivek Murthy pointed out in 2023, &ldquo;Mental health is the defining public health crisis of our time.&rdquo;</p>



<p>The company currently has 31 existing joint venture partnerships to accelerate facility growth.</p>



<p>Through Sept. 30, it had trailing 12-month adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) of $650 million, good for a 22.4% EBITDA margin.&nbsp;</p>



<p>I&rsquo;m very intrigued by Acadia&rsquo;s business.&nbsp;&nbsp;</p>



<h2>Compass Pathways (CMPS)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/mnmd_mushrooms_1600-300x169.png" alt="Dried psilocybe cubensis psilocybin magic mushrooms inside and around a plastic prescription medicine bottle with no lid isolated on white background, Mind Medicine is in the psychedelic medicine business. MNMD stock"><div>Source: Daniel Patrick Martin / Shutterstock.com</div></div>


<p><strong>Compass Pathways </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/cmps-stock-quote/"><strong>CMPS</strong></a></span>) is the smallest of three mental health stocks with a market capitalization of $629 million. Its first major treatment is the use of COMP360 psilocybin, the <a href="https://compasspathways.com/about-us/">hallucinogenic chemical</a> obtained from certain types of mushrooms, for people with treatment-resistant depression.&nbsp;</p>



<p>In December, the company <a href="https://ir.compasspathways.com/news-releases/news-release-details/compass-pathways-announces-investigational-comp360-psilocybin">announced</a> that its phase 2 study of its investigational COMP360 psilocybin treatment was well received by people who have PTSD (post-traumatic stress disorder). There were no severe adverse effects on the 22 participants.&nbsp;Dr. Guy Goodwin, Chief Medical Officer, Compass Pathways, said:</p>




<p>&ldquo;Safety is of paramount importance when developing potential new treatments, so we are pleased to see these positive safety signals. These results are consistent with findings from other studies and add to the growing body of evidence to demonstrate the potential of COMP360 in difficult-to-treat mental health conditions.&rdquo; </p>




<p>The company&rsquo;s <a href="https://finance.yahoo.com/news/wall-street-says-compass-pathways-120000983.html">phase 3 trial</a> is underway, with results expected in the summer and more by the middle of 2025.&nbsp;</p>



<p>Like most early-stage biotech firms, there are many expenses and no revenue. Compass is no different. Through the first nine months of 2023, it lost $98.5 million, about $20.3 million higher than a year earlier.&nbsp;</p>



<p>To keep the coffers full, it did a private placement in August that raised $125 million. If exercised, the warrants accompanying the American Depositary Shares (ADSs) would bring in an additional $160 million. With an exercise price of $9.93, the warrants are already in the money.&nbsp;</p>



<p>CMPS is the riskiest of the three. However, the potential reward is also relatively high if you&rsquo;re an aggressive investor.&nbsp;</p>



<p><em>On the date of publication, Will Ashworth did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guideline</a></em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">s</a><em>.</em></p>
<div><p>Will Ashworth has written about investments full-time since 2008. Publications where he&rsquo;s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/02/mental-health-mavericks-3-stocks-changing-the-game/">Mental Health Mavericks: 3 Stocks Changing the Game</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Mental Health Mavericks: 3 Stocks Changing the Game

Psychedelic therapy: FDA panel to review first ever MDMA-assisted PTSD treatment

Psychedelics Closer To Commercialization; Compass Far And Away The Leader

Psychedelic Stocks: Focus On Their Cash

ETFs&nbsp;(exchange-traded funds)&nbsp;are a cost-effective way to diversify a portfolio due to their low expense ratios compared to traditional mu...

Comments

AdvisorShares Psychedelics ETF

Notizie

Ultime notizie per AdvisorShares Psychedelics ETF (ARCA:PSIL)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO